Maraviroc Solid Drug Nanoparticles with Improved Oral Pharmacokinetics by Tatham, L et al.
It is estimated that over 36 million people are living with HIV globally and over 1 million people died from HIV in 20151. Maraviroc is an orally
dosed selective CCR5 antagonist used against CCR5-trophic HIV type-12. Maraviroc prevents the binding of HIV-1 gp160 to CCR5, which
subsequently prevents the virus from fusing with the human cell membrane, required for effective viral entry3. Maraviroc is a P-glycoprotein
(P-gp) substrate, limiting effective absorption, and it is estimated that over 60% of the absorbed drug is metabolised at first pass, primarily
by CYP3A4, resulting in a bioavailability of ~33%4. Additionally, Cmax-driven postural hypotension has been described5. The aims of this
study were to apply an emulsion-templated freeze-drying technique6 to develop and optimise maraviroc-loaded Solid Drug Nanoparticles
(SDNs) for improved oral pharmacokinetics.
1. SDN production and characterisation 2. In vitro apparent permeability
4. Tissue distribution
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An emulsion-templated
freeze-drying screen was
used to produce and
optimise solid drug
nanodispersions of MVC,
achieving up to 70 wt.%
drug-loading. Materials
used in this study are
outlined in Table 1.
MVC was initially dissolved within an internal phase of
dichloromethane-in-water emulsion, with stabilised polymers and
surfactants in the aqueous continuous phase. Following rapid
freezing and drying, the samples were reconstituted in water to
produce MVC nanodispersions and subsequently used for
pharmacological assessment.
Table 1. MVC SDNs prepared using emulsion-
templated freeze-drying and characterised using
dynamic light scattering (Malvern Instruments, UK).
The results in Figure 1. indicate that the
formulation of MVC into SDNs
increases the drugs apparent oral
absorption up to 1.7-fold compared to
conventional unformulated MVC.
Suggesting a potential increase in the
absorption of MVC from the gut and
into the systemic circulation.
Figure 1. The Papp ratio of unformulated and SDN
formulated MVC. Monolayers were incubated for
1 h at 37oC, 5% CO2. *, P<0.05 (Two-tailed paired
t-test) (±SD, n=4).
Increased MVC concentrations were observed in most of the
dissected tissues obtained from the SDN dosed rats compared to
the unformulated MVC dosed animals (Figure 3.A.). Figure 3.B.
shows increased MVC accumulation in the brain, lung, intestine,
kidney, spleen and liver with an average 1.6-fold increase. Analysis
of the heart and brain suggested slight reductions in MVC
accumulation in these tissues. Animals were humanely culled, 4-
hours post-dose, using an overdose of anaesthetic and all animal
work was conducted in accordance with the Animals (Scientific
Procedures) Act 1986 (ASPA) implemented by the UK Home Office.
Figure 3 (A & B). MVC tissue concentrations (ng/g of dissected tissue) in adult male 
Wistar rats (280-330 g) dosed with either the lead drug-loaded SDN preparation or an 
equivalent unformulated MVC dose (10 mg/Kg MVC, 10 µCi/mg 3H activity) (±SD, n=4). 
3. In vivo oral pharmacokinetics
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Enhanced pharmacokinetic exposure
was highlighted following the oral
dosing of the lead drug-loaded SDN
preparation compared to an
equivalent unformulated MVC dose
in male Wistar rats (Figure 2.A).
Specifically, Cmax, Cmin and AUC
values were shown to be 1.6-, 3.9-
and 2.4-fold greater than those
observed for unformulated MVC,
respectively. A 2.8-fold reduction in
the Cmax:Cmin ratio was also noted
in the SDN dosed animals (Figure
2.B).
Figure 2 (A). MVC plasma concentration in adult male Wistar rats (280-330 g) dosed
with either the lead drug-loaded SDN preparation or an equivalent unformulated
MVC dose (10 mg/Kg MVC, 10 µCi/mg 3H activity) via oral gavage. (B.) PK
parameters derived from the study (±SD, n=4).
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• An emulsion-templated freeze-drying screen was employed to prepare and optimise MVC SDNs with up to 70 wt.% drug-loading.
• Enhanced permeation of SDN formulated MVC was observed across differentiated Caco-2 monolayers, highlighting the potential
for improved oral absorption.
• Oral in vivo analysis suggested improved pharmacokinetic exposure and enhanced tissue accumulation.
• This study highlights the potential for improved MVC PK characteristics and the scope for dose reduction using SDN technology.
MVC 
Nanodispersion
Composition Z-average 
size (nm)
PDI
1 70% MVC; 20% PVA; 10% Tween 801.9 0.443
2 70% MVC; 20% PVA; 10% NDC 578.5 0.342
3 70% MVC; 20% PVA; 10% AOT 682.8 0.345
Tissue (n=12) Unformulated
MVC (ng/g)
MVC
nanodispersion 3
(ng/g)
Fold-
difference
Paired t-test 
(two-tailed)
Heart 81.33 74.24 0.91 P=0.696 (ns)
Brain 63.10 83.26 1.32 P=0.323 (ns)
Lung 128.60 143.90 1.12 P=0.451 (ns)
Intestine 2433.69 4136.05 1.70 P=0.056 (ns)
Kidney 130.47 231.31 1.77 P=<0.01
Spleen 167.36 282.68 1.69 P=<0.0001
Liver 167.84 375.01 2.23 P=<0.0001
Testis 107.84 100.51 0.93 P=0.819 (ns)
